Från 3 betyg inom de senaste 6 månaderna. Detta är inte en investeringsrekommendation.
Köp
33%
Behåll
33%
Sälj
33%
Om
Health Technology
Biotechnology
Manufacturing
Pharmaceutical Preparation Manufacturing
Enanta Pharmaceuticals, Inc., a biotechnology company, discovers and develops small molecule drugs for the treatment of viral infections and liver diseases. Its research and development disease targets include respiratory syncytial virus, SARS-CoV-2, human metapneumovirus, and hepatitis B virus. The company has a collaborative development and license agreement with Abbott Laboratories to identify, develop, and commercialize HCV NS3 and NS3/4A protease inhibitor compounds, including paritaprevir and glecaprevir for the treatment of chronic hepatitis C virus. Enanta Pharmaceuticals, Inc. was founded in 1995 and is headquartered in Watertown, Massachusetts.